Oditrasertib
CAS No. 2252271-93-3
Oditrasertib( —— )
Catalog No. M36303 CAS No. 2252271-93-3
Oditrasertib (DNL-788) is a potent RIPKl inhibitor with an IC50 value of less than 100 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 141 | In Stock |
|
| 5MG | 154 | In Stock |
|
| 10MG | 226 | In Stock |
|
| 25MG | 377 | In Stock |
|
| 50MG | 535 | In Stock |
|
| 100MG | 731 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1479 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOditrasertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionOditrasertib (DNL-788) is a potent RIPKl inhibitor with an IC50 value of less than 100 nM.
-
DescriptionOditrasertib is a receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 value lower than 100 nM. Oditrasertib can be used for the research of diseases involving inflammation or cell death.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetRIP kinase
-
RecptorRIP kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2252271-93-3
-
Formula Weight295.28
-
Molecular FormulaC14H15F2N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC1=CN=CC2=C1OCCN(C(=O)C(C)(C)C(F)F)C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fidalgo JDV, et al. Preparation of substituted oxazepines and related compounds as RIPK1 inhibitors and uses thereof. WO2018213632A1. 2018-11-22.
molnova catalog
related products
-
GSK-843
GSK-843 (GSK'843) is a selective and potent RIP3 inhibitor with an IC50 value of 8.6 nM for the structural domain of RIP3 kinase.
-
Necrostatin-34
Necrostatin-34 is a RIPK1 kinase inhibitor, stabilizing RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.
-
GSK2593074A
GSK2593074A (GSK'074, GSK-2593074A) is novel potent, selective RIP1/RIP3 kinase dual inhibitor.
Cart
sales@molnova.com